StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Iovance Biotherapeut
16.96
+1.01%
 

IOVA

 

Iovance Biotherapeutics

$ 16.96

 
+$0.17 | +1.01%
 
 
Open
$ 18.10
 
 
MKT CAP
$ 4.74B
 
High
$ 18.24
 
 
VOL
$ 11.54M
 
Low
$ 16.62
 
 
AVG VOL
$ 12.50M
 
 
 

IOVA Stock Analysis

  Login to display Iovance Biotherapeutics (IOVA) recommendation from the last 90 days from financial news and social media.
 
 

IOVA Total Score

 
 

Strengths

IOVA Rewards

 Earnings are forecast to grow

 

Risk Analysis

IOVA Risk Analysis

 Insider selling during the past 3 months

 
 

Chart

 
 

8.08

6.38

3.33

6.49

 
 
1month
3month
6month
1year
 
Total Return
IOVA
vs.
S&P500
 

 
1-week Return
-2.92%
 
+1.04%
 
 
5-week Return
+123.45%
 
+4.91%
 
 
10-week Return
+116.88%
 
+7.60%
 
 
 

IOVA Risk Level

This Indicator assigning IOVA risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
IOVA Risk Level
LOW
HIGH

Risk Volatility

 

IOVA has Low Risk Level

Click here to check what is your level of risk

 

IOVA Analysts Opinion

IOVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

IOVA Earnings Sentiment

 Below analyst estimate

IOVA Earnings Sentiment

 Sales decline

 
 

Rating

×
 

Rating

5.00
 
 

Momentum

×
 

Momentum

3.67
 

IOVA Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.45
 

IOVA Activity Sentiment

 Insider selling during the past 3 months

 

Future

×
 

Future

3.83
 

IOVA Future Sentiment

 Earnings are forecast to grow

 
 

IOVA Analysts Opinion

IOVA Analysts opinion is negative and it remained unchanged from the past 3 months

 

IOVA Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
72%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
75%
83%
 
On Track
On Track
On Track
 

IOVA Street Opinion 

IOVA Street view is bullish and have positive views on the near-term outlook

 

IOVA Performance Sentiment

Sentiments overview associated with IOVA events and the stock performance.
 
72%
23%
Positive
Negative
31 out of 43
events present
10 out of 43
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

IOVA Earnings

The TTM reflects 12-month period, providing review of IOVA financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
1
-
 
 
Operating Exp
441
399
343
+13.39%
 
 
Operating Inc
-446
-399
-343
-
 
 
Net Interest Inc
12
3
-
 
 
Interest Inc
12
3
-
 
 
EPS
-2.08
-2.49
-2.23
-
 
 
 
Highlights
Last Modify
Price
% Change

 
Approvals
Today
16.96
+1.01%
 
Insider Selling
This Week
16.79
+5.53%
 
Weak Earnings
This Week
15.91
-8.72%
 
Weak Earnings
This Week
17.43
-0.23%
 
Options Activity
1 Week Ago
15.94
+1.08%
 
 
 
joker
 
 
 
StocksRunner

Explore our IOVA Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our IOVA Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

IOVA Rewards

 Earnings are forecast to grow

 

Risk Analysis

 

IOVA Risk Analysis

 Insider selling during the past 3 months

 
 
 

IOVA Risk Level

 
 
 

The Indicator assigning IOVA risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
IOVA Risk Level
LOW
HIGH

Risk Volatility

 

IOVA has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

IOVA

 

Iovance Biotherapeutics

$ 16.96

 
+$0.17 | +1.01%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 18.10
 
 
MKT CAP
$ 4.74B
 
High
$ 18.24
 
 
VOL
$ 11.54M
 
Low
$ 16.62
 
 
AVG VOL
$ 12.50M
 
 
 

IOVA Analysis

  Sign in to view Iovance Biotherapeutics (IOVA) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

8.08

6.38

3.33

6.49

 
 
1month
3month
6month
1year
 
Total Return
IOVA
vs.
S&P500
 

 
1-week Return
-2.92%
 
+1.04%
 
 
5-week Return
+123.45%
 
+4.91%
 
 
10-week Return
+116.88%
 
+7.60%
 
 
 

IOVA Analysts Opinion

IOVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

IOVA Earnings Sentiment

 Below analyst estimate

IOVA Earnings Sentiment

 Sales decline

 
 

Rating

×
 

Rating

5.00
 
 

Momentum

×
 

Momentum

3.67
 

IOVA Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.45
 

IOVA Activity Sentiment

 Insider selling during the past 3 months

 

Future

×
 

Future

3.83
 

IOVA Future Sentiment

 Earnings are forecast to grow

 
 

IOVA Analysts Opinion

IOVA Analysts opinion is negative and it remained unchanged from the past 3 months

 

IOVA Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
72%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
75%
83%
 
On Track
On Track
On Track
 

IOVA Street Opinion 

IOVA Street view is bullish and have positive views on the near-term outlook

 
IOVA Performance Sentiment
Sentiments overview associated with IOVA events and the stock performance.
 
72%
23%
Positive
Negative
31 out of 43
events present
10 out of 43
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

IOVA Earnings

The TTM data reflects the most recent 12-month period, providing overview of IOVA financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
1
-
 
 
Operating Exp
441
399
343
+13.39%
 
 
Operating Inc
-446
-399
-343
-
 
 
Net Interest Inc
12
3
-
 
 
Interest Inc
12
3
-
 
 
EPS
-2.08
-2.49
-2.23
-
 
 
Highlights
Last Modify
Price
% Change

 
Approvals
Today
16.96
+1.01%
 
Insider Selling
This Week
16.79
+5.53%
 
Weak Earnings
This Week
15.91
-8.72%
 
Weak Earnings
This Week
17.43
-0.23%
 
Options Activity
1 Week Ago
15.94
+1.08%
 
 
IOVA Latest News Feed

Iovance stock rises after FDA lifts clinical hold on lung cancer trial.

Today

Activity
Momentum

FDA Lifts Clinical Hold On Iovance Biotherapeutics IOV-LUN-202 Study In Non-Small Cell Lung Cancer . (RTTNews) - Iovance Biotherapeutics Inc. (IOVA) Monday said the Food and Drug Administration (FDA) has lifted a partial clinical hold placed on the registrational IOV-LUN-202 study of its LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC).

Today

Activity

Iovance Biotherapeutics to Present at Upcoming Conferences. SAN CARLOS Calif. March 01 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics Inc. (NASDAQ: IOVA) a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer today announced that senior leadership plans to present at the following conferences:

Fri Mar 1, 2024

Activity

(IOVA) - Analyzing Iovance Biotherapeuticss Short Interest. ) short percent of float has fallen 6.67% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...Full story available on Benzinga.com

Fri Mar 1, 2024

Activity
Momentum

Why Iovance Biotherapeutics Stock Got Trounced on Thursday. Iovance Biotherapeutics (NASDAQ: IOVA) one of the more high-flying biotech stocks of late fell earthward in trading on Thursday. This was a direct consequence of its latest quarterly figures and operational update that were published after hours on Wednesday and received a fairly negative#iovance #fda #amtagvi #frederickvogt #vogt #ericvolkman #motleyfool

Fri Mar 1, 2024

Momentum

Iovances (IOVA) Q4 Earnings & Sales Fall Short of Estimates. Iovance Biotherapeutics Inc. IOVA incurred a loss of 45 cents per share in fourth-quarter 2023 wider than the Zacks Consensus Estima

Thu Feb 29, 2024

Earnings

Iovance Biotherapeutics (IOVA) Reports Q4 Loss Misses Revenue Estimates. Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of

Wed Feb 28, 2024

Earnings

Iovance Biotherapeutics GAAP EPS of -$0.45 misses by $0.01 revenue of $0.48M misses by $0.92M.

Wed Feb 28, 2024

Earnings

1 Soaring Growth Stock That Could Rise Another 53% According to Wall Street. Investors looking for stocks that can produce swift and dramatic gains recently found what they wanted with Iovance Biotherapeutics (NASDAQ: IOVA). Over the past three

Mon Feb 26, 2024

Momentum

This Biotech Stock Has 47% Upside According to 1 Wall Street Analyst. With shares of Iovance Biotherapeutics (NASDAQ: IOVA) soaring by 175% in the last three months Wells Fargo analyst Yanan Zhu thinks they could still go as much as 47% higher.

Fri Feb 23, 2024

Momentum
Potential

Iovance Biotherapeutics Unusual Options Activity For February 22. Financial giants have made a conspicuous ish move on Iovance Biotherapeutics. Our analysis of options history for Iovance Biotherapeutics (NASDAQ:) revealed 23 unusual trades. Delving into

Thu Feb 22, 2024

Momentum
Potential

New cancer therapy approved by FDA supercharges bodys immune system. After undergoing surgery radiation and three different therapies Scott Goedeke faced a tough reality: The cancer that first surfaced on the roof of his mouth had spread to a lymph node i

Wed Feb 21, 2024

Activity

Iovance rallies nearly 40% on FDA approval stock offering.

Tue Feb 20, 2024

Activity
Activity
Momentum

Why Iovance Biotherapeutics Stock Is Skyrocketing Today.

Tue Feb 20, 2024

Momentum

Iovance Prices Public Offering Of $211 Mln Of Shares. Stock Up Over 25% In Pre-market. (RTTNews) - Iovance Biotherapeutics Inc. (IOVA) a company focused on novel polyclonal tumor infiltrating lymphocyte therapies for cancer patients on Tuesday a

Tue Feb 20, 2024

Activity
Momentum

Stock Rises on FDA Nod for Melanoma Drug Amtagvi. Shares of Iovance Biotherapeutics Inc. IOVA were up 32.7% in after-hours trading on Feb 16 after the company announced that the FDA has granted an accelerated approval to its T cell immunotherapy Amtagvi (

Tue Feb 20, 2024

Activity
Momentum

Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi. Shares of Iovance Biotherapeutics Inc. IOVA were up 32.7% in after-hours trading on Feb 16 after the company announced that the

Mon Feb 19, 2024

Activity
Momentum

In major milestone FDA approves first cell therapy for solid tumors. Nearly four decades after its first conception the first TIL therapy an immunotherapy that harvests cancer-fighting immune cells from the patients own body received accelerated approval

Sat Feb 17, 2024

Activity

US FDA grants accelerated approval for Iovances skin cancer cell therapy. Iovance Biotherapeutics said on Friday the United States health regulator had granted accelerated approval for its cell therapy for adult patients with advanced melanoma t

Fri Feb 16, 2024

Activity

Iovance Biotherapeutics to Host Conference Call and Webcast on Friday February 16 2024. SAN CARLOS Calif. Feb. 16 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics Inc. (NASDAQ: IOVA) a biotechnology company focused on innovating developing and deliverin

Fri Feb 16, 2024

Activity

Iovances AMTAGVI™ (lifileucel) Receives United States FDA Accelerated Approval for Advanced Melanoma. AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted t

Fri Feb 16, 2024

Activity

Iovance gets FDA accelerated approval for advanced melanoma therapy.

Fri Feb 16, 2024

Activity

3 Opportunities for Iovance Biotherapeutics Stock and 1 Risk. In investing and in life its rare for opportunities to be without accompanying risks just as its rare for clouds to be without silver linings if one looks hard enough. On that note Io

Mon Feb 12, 2024

Potential

iova factor-based stock analysis - benjamin graham. below is valideas guru fundamental report for iovance biotherapeutics inc (iova). of the 22 guru strategies we follow iova rates highest using our value investor model based on the published s

Wed Jan 31, 2024

Potential

commit to purchase iovance biotherapeutics at $5 earn 27% using options. investors eyeing a purchase of iovance biotherapeutics inc (symbol: iova) shares but tentative about paying the going market price of $8.37/share might benefit from con

Tue Jan 16, 2024

Activity
Potential

insiders were right: iova makes new 52-week high. in trading on monday shares of iovance biotherapeutics inc (symbol: iova) touched a new 52-week high of $9.50/share. thats a 195.95% rise or $6.29 per share from the 52-week low of $3.21 set

Mon Jan 8, 2024

Momentum

 
 
 
 
 

Score Tracker

 
 
 
Based on 43 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 16:31 Wall St. time
 
 

IOVA Total Score

 
 
 
 
 
 
 
StocksRunner

Discover IOVA Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of IOVA. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our IOVA Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

IOVA Stock trends

IOVA Stock performance

IOVA Stock analysis

IOVA investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker